OpenAlex 2,408 works 81 author topics
Works
2,408 works
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials that showed ef…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND: The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refracto…
-
YÖKSİS
SJR Q1
JCR Q1
As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their i…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50% of patients. Robust data from phase 3 randomized studies evaluating second-line therapy for chronic GVHD are lacking. In…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 100.0%
BACKGROUND Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50% of patients. Robust data from phase 3 randomized studies evaluating second-line therapy for chronic GVHD are lacking. In…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.8%
No abstract yet.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 10%
OpenAlex 96.1%
Antiapoptotic members of the bcl-2 family have recently been implicated in the pathogenesis of chronic myeloid leukemia (CML), a hematopoietic neoplasm associated with the BCR/ABL oncogene. We have examined expression of MCL-1 in primary CML cells and BCR/ABL-transformed cell lines. Independent of the phase of disease…
-
OpenAlex top 1%
OpenAlex 99.4%
Sixty-four patients with hairy-cell leukemia (HCL) (61 had undergone prior splenectomy) were treated with alpha-2 interferon (Intron A, Schering Corp, Kenilworth, NJ) subcutaneously three times per week at a dosage of 2 X 10(6) U/m2. Three patients (5%) demonstrated a complete response (CR) with apparent eradication o…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.4%
Imatinib mesylate (IM), 400 mg daily, is the standard treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML). Preclinical data and results of single-arm studies raised the suggestion that better results could be achieved with a higher dose. To investigate whether the systematic use of a higher dose…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.4%
Imatinib mesylate (IM), 400 mg daily, is the standard treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML). Preclinical data and results of single-arm studies raised the suggestion that better results could be achieved with a higher dose. To investigate whether the systematic use of a higher dose…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex top 1%
OpenAlex 99.2%
Long-term follow-up of prospective studies comparing allogeneic transplantation to autologous transplantation in multiple myeloma is few and controversial. This is an update at a median follow-up of 96 months of the European Group for Blood and Marrow Transplantation Non-Myeloablative Allogeneic stem cell transplantat…
-
OpenAlex top 1%
OpenAlex 99.6%
Methotrexate (MTX) transport was examined in 27 patients with untreated acute lymphocytic leukemia (ALL) and 31 patients with relapsed ALL using a previously described fluorescent MTX analog (PT430) displacement assay (Blood 80:1158, 1992). Only 13% of untreated patients were considered to have impaired MTX transport,…
Academicians
81 academicians
- AHMET EMRE EŞKAZAN 118 author topics
- GÜRAY SAYDAM 73 author topics
- OSMAN İLHAN 60 author topics
- MUHİT ÖZCAN 54 author topics
- GÜNHAN GÜRMAN 47 author topics
- MUHLİS CEM AR 44 author topics
- BİROL GÜVENÇ 32 author topics
- SİNEM CİVRİZ BOZDAĞ 25 author topics
- CUMHUR GÜNDÜZ 24 author topics
- BURÇİN KAYMAZ 22 author topics
- MELTEM YÜKSEL 21 author topics
- ÖMÜR GÖKMEN SEVİNDİK 21 author topics